<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01602055</url>
  </required_header>
  <id_info>
    <org_study_id>XXI/32/CL/2009</org_study_id>
    <nct_id>NCT01602055</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Study of Two Azithromycin Tablet Formulations in Indonesian Healthy Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Novell Pharmaceutical Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT Novell Pharmaceutical Laboratories</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the bioequivalence of 500 mg Azithromycin FC tablets
      (Azivol) produced by PT. Novell Pharmaceutical Laboratories, compared to the reference
      product Zithromax 500 mg FC tablet produced by Pfizer Australia Pty, Ltd
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of azithromycin until 120 h after oral administration of 500 mg Azithromycin tablet (ng/mL)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Fasting</condition>
  <arm_group>
    <arm_group_label>Azivol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Zithromax</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Single dose 500 mg of film coated tablet</description>
    <arm_group_label>Azivol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Single dose 500 mg of film coated tablet</description>
    <arm_group_label>Zithromax</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects, both sexes, age between 18 to 55 years old

          -  Weight with normal range according to accepted normal values for BMI (18-25 kg/m2)

          -  Give a written informed consent

          -  Acceptable medical history and physical examination

          -  Normal hematology values including hemoglobin, hematocrit, WBC, platelets, WBC
             differential

          -  Normal laboratory test including : Blood urea nitrogen, sGPT, sGOT, alkaline
             phosphatase, total bilirubin, total protein, fasting glucose, albumin and creatinine

          -  Normal urinalysis results including: specific gravity, color, pH, sugar, albumin,
             bilirubin, RBC, WBC and casts

          -  Acceptable electrocardiogram (ECG) result

          -  Negative result for serological tests of Hepatitis B, Hepatitis C and HIV

          -  Negative result for pregnancy test

        Exclusion Criteria:

          -  Smoker or alcoholism

          -  Pregnant woman or nursing mother

          -  Have history of hepatic, cardiovascular, gastrointestinal or renal disease

          -  Potentially sensitive to azithromycin or other related drugs

          -  Received any investigation drug within four weeks

          -  Donation or loss more than 450 mL of blood within 3 months prior to the screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yahdiana Harahap, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indonesia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PT Clinisindo Laboratories</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2012</study_first_submitted>
  <study_first_submitted_qc>May 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2012</study_first_posted>
  <last_update_submitted>May 17, 2012</last_update_submitted>
  <last_update_submitted_qc>May 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

